The Cancer Letter

Inside information on cancer research and drug development

COVID-19 & Cancer

Herd immunity is achievable, but it will be tight, Francis Collins, other AACR panelists say

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In surveys, as many as 15% of Americans say that they will not get a COVID-19 vaccine under any circumstances, and another 17% are in the “wait-and-see” category, holding out to observe how others fare.

If these numbers are correct, the U.S. has almost no wiggle room as it strives to reach herd immunity to COVID-19. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account